NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.
CASRN: 152923-56-3
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of daclizumab during breastfeeding. Because daclizumab is a large protein molecule with a molecular weight of about 144,000 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Until more data become available, daclizumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Some authors recommend avoiding breastfeeding with daclizumab.[1,2]
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
(Multiple Sclerosis) Glatiramer, Immune Globulin, Interferon Beta
References
- 1.
- Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler. 2013;19:835–43. [PubMed: 23319073]
- 2.
- Almas S, Vance J, Baker T, et al. Management of multiple sclerosis in the breastfeeding mother. Mult Scler Int. 2016;2016:6527458. [PMC free article: PMC4757692] [PubMed: 26966579]
Substance Identification
Substance Name
Daclizumab
CAS Registry Number
152923-56-3
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- LactMed App
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- Review Basiliximab[Drugs and Lactation Database (...]Review Basiliximab. Drugs and Lactation Database (LactMed). 2006
- Review Tildrakizumab[Drugs and Lactation Database (...]Review Tildrakizumab. Drugs and Lactation Database (LactMed). 2006
- Review Abciximab[Drugs and Lactation Database (...]Review Abciximab. Drugs and Lactation Database (LactMed). 2006
- Review Mepolizumab[Drugs and Lactation Database (...]Review Mepolizumab. Drugs and Lactation Database (LactMed). 2006
- Review Pembrolizumab[Drugs and Lactation Database (...]Review Pembrolizumab. Drugs and Lactation Database (LactMed). 2006
- Daclizumab - Drugs and Lactation Database (LactMed)Daclizumab - Drugs and Lactation Database (LactMed)
Your browsing activity is empty.
Activity recording is turned off.
See more...